Client Blend Therapeutics Completes Successful Launch
January 9, 2012
Foley Hoag LLP congratulates its client Blend Therapeutics on its successful launch.
Blend Therapeutics was founded by three leaders in the fields of nanomedicine and chemistry: Dr. Robert Langer and Dr. Stephen Lippard of Massachusetts Institute of Technology, and Dr. Omid Farokhzad of Harvard Medical School. The company is focused on combination medicines stemming from its proprietary Maestro™ platform, which is expected to target the underlying mechanisms of cancer and other complex diseases.
Foley Hoag, led by partner Jeffrey Quillen, co-chair of the firm’s Life Sciences Practice Group, has represented Blend Therapeutics from its inception. Quillen also represents Selecta Biosciences Inc. and Bind Biosciences, biotechnology startups founded by Farokhzad and Langer.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.